INCY

SEC source: 0001209191-17-044425 · doc4.xml · nonDerivative · entry 2

Trower Paul · CIK 0001642041 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,148

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-044425 · doc4.xml · nonDerivative · entry 1

Trower Paul · CIK 0001642041 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,148

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Mr. Trower's continued service with the Issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.

SEC source: 0001209191-17-044420 · doc4.xml · derivative · entry 3

GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 779

Underlying: Common Stock · 779 shares

Expires 2027-07-04

F3 · derivative.exercise_date: Beginning July 5, 2017, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

SEC source: 0001209191-17-044420 · doc4.xml · derivative · entry 2

GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,349

Underlying: Common Stock · 11,349 shares

Expires 2027-07-04

F3 · derivative.exercise_date: Beginning July 5, 2017, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

SEC source: 0001209191-17-044420 · doc4.xml · nonDerivative · entry 1

GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,532

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Mr. Gryska's continued service with the Issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Includes an aggregate of 19,015 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-17-044422 · doc4.xml · derivative · entry 2

Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,168

Underlying: Common Stock · 47,168 shares

Expires 2027-07-04

F3 · derivative.exercise_date: Beginning July 5, 2017, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

SEC source: 0001209191-17-044422 · doc4.xml · nonDerivative · entry 1

Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 371,992

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Mr. Hoppenot's continued service with the Issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Includes an aggregate of 244,637 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-17-044416 · doc4.xml · derivative · entry 2

Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,128

Underlying: Common Stock · 12,128 shares

Expires 2027-07-04

F3 · derivative.exercise_date: Beginning July 5, 2017, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

SEC source: 0001209191-17-044416 · doc4.xml · nonDerivative · entry 1

Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,284

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Mr. Yao's continued service with the Issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Includes an aggregate of 11,187 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-17-044412 · doc4.xml · derivative · entry 3

Iyengar Vijay K · CIK 0001670000 · EVP GPS, BD, & Licensing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 779

Underlying: Common Stock · 779 shares

Expires 2027-07-04

F3 · derivative.exercise_date: Beginning July 5, 2017, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

SEC source: 0001209191-17-044412 · doc4.xml · derivative · entry 2

Iyengar Vijay K · CIK 0001670000 · EVP GPS, BD, & Licensing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,349

Underlying: Common Stock · 11,349 shares

Expires 2027-07-04

F3 · derivative.exercise_date: Beginning July 5, 2017, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

SEC source: 0001209191-17-044412 · doc4.xml · nonDerivative · entry 1

Iyengar Vijay K · CIK 0001670000 · EVP GPS, BD, & Licensing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,510

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Dr. Iyengar's continued service with the Issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Includes an aggregate of 4,632 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-17-044409 · doc4.xml · derivative · entry 3

Siegel Eric H. · CIK 0001527573 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 779

Underlying: Common Stock · 779 shares

Expires 2027-07-04

F3 · derivative.exercise_date: Beginning July 5, 2017, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

SEC source: 0001209191-17-044409 · doc4.xml · derivative · entry 2

Siegel Eric H. · CIK 0001527573 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,349

Underlying: Common Stock · 11,349 shares

Expires 2027-07-04

F3 · derivative.exercise_date: Beginning July 5, 2017, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

SEC source: 0001209191-17-044409 · doc4.xml · nonDerivative · entry 1

Siegel Eric H. · CIK 0001527573 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,733

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Mr. Siegel's continued service with the Issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Includes an aggregate of 11,187 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-17-044406 · doc4.xml · derivative · entry 2

Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,128

Underlying: Common Stock · 12,128 shares

Expires 2027-07-04

F3 · derivative.exercise_date: Beginning July 5, 2017, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

SEC source: 0001209191-17-044406 · doc4.xml · nonDerivative · entry 1

Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,554

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Mr. Huber's continued service with the Issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Includes an aggregate of 11,187 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-17-044403 · doc4.xml · derivative · entry 3

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 779

Underlying: Common Stock · 779 shares

Expires 2027-07-04

F3 · derivative.exercise_date: Beginning July 5, 2017, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

SEC source: 0001209191-17-044403 · doc4.xml · derivative · entry 2

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,349

Underlying: Common Stock · 11,349 shares

Expires 2027-07-04

F3 · derivative.exercise_date: Beginning July 5, 2017, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

SEC source: 0001209191-17-044403 · doc4.xml · nonDerivative · entry 1

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,067

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Ms. Swain's continued service with the Issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Includes an aggregate of 11,187 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-17-044394 · doc4.xml · derivative · entry 2

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,128

Underlying: Common Stock · 12,128 shares

Expires 2027-07-04

F3 · derivative.exercise_date: Beginning July 5, 2017, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

SEC source: 0001209191-17-044394 · doc4.xml · nonDerivative · entry 1

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,165

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Mr. Stein's continued service with the Issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Includes an aggregate of 14,648 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-17-043653 · doc4.xml · derivative · entry 3

Siegel Eric H. · CIK 0001527573 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,572

Underlying: Common Stock · 1,820 shares

Expires 2021-01-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Beginning January 21, 2014, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years.

SEC source: 0001209191-17-043653 · doc4.xml · nonDerivative · entry 2

Siegel Eric H. · CIK 0001527573 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,216

F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.

F2 · balance_after: This includes an aggregate of 11,187 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-17-043653 · doc4.xml · nonDerivative · entry 1

Siegel Eric H. · CIK 0001527573 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,036

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-043339 · doc4.xml · nonDerivative · entry 1

DIXON WENDY L · CIK 0001202283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,962

F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.

SEC source: 0001638599-17-000677 · doc4_4839.xml · nonDerivative · entry 6

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

14159, L.P. · CIK 0001551138 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 787,387

F4 · ownership.nature: 150 shares of common stock (the "Common Stock") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of director retainer fees of $19,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's Board of Directors (the "Board") as a representative of the Funds (as defined below).

F5 · ownership.nature: Pursuant to the policies of Baker Bros. Advisors LP (the "Adviser"), Julian C. Baker does not have any right to the pecuniary interest in the Issuer's securities issued in lieu of director retainer fees and the Funds (as defined below) are entitled to an indirect proportionate pecuniary interest in the securities issued in lieu of director fees. 667, L.P. ("667"), Baker Brothers Life Sciences, L.P. ("Life Sciences") and 14159, L.P. ("14159", and together with 667, and Life Sciences, the "Funds") each owns an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees (ie. no direct pecuniary interest).

F8 · ownership.nature: As a result of Felix J. Baker's and Julian C. Baker's ownership interest in 14159 Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 787,387 shares of common stock of the Issuer beneficially owned by 14159, a limited partnership of which the sole general partner is 14159 Capital, L.P., a limited partnership of which the sole general partner is 14159 Capital (GP), LLC, due to 14159 Capital, L.P.'s right to receive an allocation of a portion of the profits from 14159. Includes beneficial ownership of 1,710 shares issued pursuant to the Stock Incentive Plan in lieu of director retainer fees and 95,000 shares received previously from exercise of 95,000 stock options of the Issuer that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion.

F9 · ownership.nature: The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F10 · ownership.nature: The 150 shares are reported for each of the Funds as each has an indirect pecuniary interest.

SEC source: 0001638599-17-000677 · doc4_4839.xml · nonDerivative · entry 5

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

14159, L.P. · CIK 0001551138 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 29,161,945

F4 · ownership.nature: 150 shares of common stock (the "Common Stock") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of director retainer fees of $19,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's Board of Directors (the "Board") as a representative of the Funds (as defined below).

F5 · ownership.nature: Pursuant to the policies of Baker Bros. Advisors LP (the "Adviser"), Julian C. Baker does not have any right to the pecuniary interest in the Issuer's securities issued in lieu of director retainer fees and the Funds (as defined below) are entitled to an indirect proportionate pecuniary interest in the securities issued in lieu of director fees. 667, L.P. ("667"), Baker Brothers Life Sciences, L.P. ("Life Sciences") and 14159, L.P. ("14159", and together with 667, and Life Sciences, the "Funds") each owns an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees (ie. no direct pecuniary interest).

F7 · ownership.nature: As a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest 29,161,945 shares of common stock of the Issuer beneficially owned by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. Includes beneficial ownership of 1,710 shares issued pursuant to the Stock Incentive Plan in lieu of director retainer fees and 95,000 shares received previously from exercise of 95,000 stock options of the Issuer that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion.

F9 · ownership.nature: The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F10 · ownership.nature: The 150 shares are reported for each of the Funds as each has an indirect pecuniary interest.

SEC source: 0001638599-17-000677 · doc4_4839.xml · nonDerivative · entry 4

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

14159, L.P. · CIK 0001551138 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,374,249

F4 · ownership.nature: 150 shares of common stock (the "Common Stock") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of director retainer fees of $19,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's Board of Directors (the "Board") as a representative of the Funds (as defined below).

F5 · ownership.nature: Pursuant to the policies of Baker Bros. Advisors LP (the "Adviser"), Julian C. Baker does not have any right to the pecuniary interest in the Issuer's securities issued in lieu of director retainer fees and the Funds (as defined below) are entitled to an indirect proportionate pecuniary interest in the securities issued in lieu of director fees. 667, L.P. ("667"), Baker Brothers Life Sciences, L.P. ("Life Sciences") and 14159, L.P. ("14159", and together with 667, and Life Sciences, the "Funds") each owns an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees (ie. no direct pecuniary interest).

F6 · ownership.nature: As a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Biotech Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 4,374,249 shares of common stock of the Issuer beneficially owned by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP),LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. Includes beneficial ownership of 1,710 shares issued pursuant to the Stock Incentive Plan in lieu of director retainer fees and 95,000 shares received previously from exercise of 95,000 stock options of the Issuer that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion.

F9 · ownership.nature: The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F10 · ownership.nature: The 150 shares are reported for each of the Funds as each has an indirect pecuniary interest.

SEC source: 0001209191-17-043327 · doc4.xml · nonDerivative · entry 1

BROOKE PAUL A · CIK 0001175940 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,121

F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.

SEC source: 0001209191-17-043305 · doc4.xml · nonDerivative · entry 1

BIENAIME JEAN JACQUES · CIK 0001221590 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,792

F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.

SEC source: 0001209191-17-043277 · doc4.xml · derivative · entry 3

GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,591

Underlying: Common Stock · 599 shares

Expires 2022-01-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Beginning January 8, 2015, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years.

SEC source: 0001209191-17-043277 · doc4.xml · nonDerivative · entry 2

GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,015

F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.

F2 · balance_after: This includes an aggregate of 19,015 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-17-043277 · doc4.xml · nonDerivative · entry 1

GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,614

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-041385 · doc4.xml · derivative · entry 6

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,878

Underlying: Common Stock · 6,013 shares

Expires 2022-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Beginning March 2, 2015, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years.

SEC source: 0001209191-17-041385 · doc4.xml · derivative · entry 5

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,392

Underlying: Common Stock · 3,870 shares

Expires 2023-01-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Beginning January 7, 2016, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years

SEC source: 0001209191-17-041385 · doc4.xml · nonDerivative · entry 4

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,648

F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.

F2 · balance_after: This includes an 14,648 aggregate of shares of common stock issuable pursuant to previously reported restricted stock units that have not vested

SEC source: 0001209191-17-041385 · doc4.xml · nonDerivative · entry 3

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,661

F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.

SEC source: 0001209191-17-041385 · doc4.xml · nonDerivative · entry 2

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,531

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-041385 · doc4.xml · nonDerivative · entry 1

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,518

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-039856 · doc4.xml · derivative · entry 3

GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,190

Underlying: Common Stock · 16,756 shares

Expires 2022-01-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Beginning January 8, 2015, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years.

SEC source: 0001209191-17-039856 · doc4.xml · nonDerivative · entry 2

GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,015

F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.

F2 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated.

F3 · price: Represents weighted average sale price. Actual sale prices ranged from $115.35 - $120.00.

F4 · balance_after: This includes an aggregate of 19,015 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-17-039856 · doc4.xml · nonDerivative · entry 1

GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,771

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-038296 · doc4.xml · derivative · entry 4

Siegel Eric H. · CIK 0001527573 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 977 shares

Expires 2021-01-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Beginning January 21, 2014, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years.

SEC source: 0001209191-17-038296 · doc4.xml · derivative · entry 3

Siegel Eric H. · CIK 0001527573 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,041

Underlying: Common Stock · 315 shares

Expires 2022-01-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Beginning January 8, 2015, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years.

SEC source: 0001209191-17-038296 · doc4.xml · nonDerivative · entry 2

Siegel Eric H. · CIK 0001527573 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,216

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This includes an aggregate of 11,187 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-17-038296 · doc4.xml · nonDerivative · entry 1

Siegel Eric H. · CIK 0001527573 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,239

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-038279 · doc4.xml · derivative · entry 3

Trower Paul · CIK 0001642041 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,187

Underlying: Common Stock · 3,000 shares

Expires 2019-01-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Beginning January 19, 2012, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years

SEC source: 0001209191-17-038279 · doc4.xml · nonDerivative · entry 2

Trower Paul · CIK 0001642041 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,950

F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.

F2 · balance_after: This includes an 4,380 aggregate of shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-17-038279 · doc4.xml · nonDerivative · entry 1

Trower Paul · CIK 0001642041 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,950

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.